Sionna Therapeutics, Inc. (SION): Net Income
-$75.27M
Year ended 2025-12-31
-$97.38M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$75.27M | n/m | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | -$61.69M | n/a | 2026-03-02, From 2024-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Sionna Therapeutics, Inc. (SION) | 2025-12-31 | -$75.27M | n/m |
| Omeros Corp (OMER) | 2025-12-31 | -$3.35M | n/m |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | -$244.09M | n/m |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | -$171.30M | n/m |
| Liquidia Corp (LQDA) | 2025-12-31 | -$68.92M | n/m |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | -$142.62M | n/m |
| Rocket Pharmaceuticals, Inc. (RCKT) | 2025-12-31 | -$223.12M | n/m |
| Amylyx Pharmaceuticals, Inc. (AMLX) | 2025-12-31 | -$144.74M | n/m |
| ArriVent BioPharma, Inc. (AVBP) | 2025-12-31 | -$166.31M | n/m |
Compare SION, OMER, PRTA, SPRY side by side · Screen every company in Pharmaceutical Preparations ↗